Clinical and Public Health

The Australasian COVID-19 Trial (ASCOT) is a randomised controlled trial that will generate clinical evidence about treatments for COVID-19. The ASCOT trial is being run as an Adaptive Platform Trial (APT), allowing for the study to have multiple interventions in a disease or condition by adding or removing treatment interventions to the trial as resulting data is generated and analysed. The trial will recruit patients hospitalised with COVID-19 who do not yet require intensive care support, with the aim of preventing deterioration to the point of requiring intensive care. The ASCOT trial collaborates closely with another COVID-19 platform trial – the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP), that evaluates the efficacy and safety of particular drugs to treat patients admitted to intensive care with community-acquired pneumonia.